A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare BAT1806/BIIB800, a Tocilizumab Biosimilar, with Tocilizumab Reference Product in Participants with Moderate-to-severe Rheumatoid Arthritis with Inadequate Response to Methotrexate: Treatment Period 2 Analysis (week 24 to Week 48)
Arthritis Research & Therapy（2024）
Key words
Rheumatoid arthritis,Biosimilar pharmaceuticals,Tocilizumab,Treatment switching
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined